All-Cure Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 18-07-2024
- Paid Up Capital ₹ 0.96 M
as on 18-07-2024
- Company Age 30 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 0.60 M
as on 18-07-2024
- Revenue 19.57%
(FY 2023)
- Profit 26.20%
(FY 2023)
- Ebitda -40.13%
(FY 2023)
- Net Worth 19.47%
(FY 2023)
- Total Assets 16.23%
(FY 2023)
About All-Cure Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.96 M.
The company currently has active open charges totaling ₹0.60 M.
Manoj Sharma, Shiv Sharma, and Jitender Sharma serve as directors at the Company.
- CIN/LLPIN
U74899DL1994PTC062225
- Company No.
062225
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Oct 1994
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
New Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at All-Cure Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manoj Sharma  | Managing Director | 30-Dec-2021 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shiv Sharma | Director | 28-Oct-2002 | Current |
| Jitender Sharma | Director | 19-Oct-1994 | Current |
Financial Performance of All-Cure Pharma.
All-Cure Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.57% increase. The company also saw a substantial improvement in profitability, with a 26.2% increase in profit. The company's net worth Soared by an impressive increase of 19.47%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of All-Cure Pharma?
In 2023, All-Cure Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.60 M
₹0
Charges Breakdown by Lending Institutions
- Vijaya Bank : 0.06 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 13 Mar 2014 | Vijaya Bank | ₹0.60 M | Open |
How Many Employees Work at All-Cure Pharma?
Unlock and access historical data on people associated with All-Cure Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of All-Cure Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped All-Cure Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
